Retracted Alzheimer Study Flagged for Image Manipulation and Data Duplication

Scientific retractions matter deeply to clinicians and researchers who rely on published data to guide therapeutic decisions. When a study is retracted for data manipulation, it can invalidate years of follow-on research and erode trust in an entire line of inquiry. This case is a cautionary example from the Alzheimer's and neurodegeneration field.

The original 2018 paper, published in Aging Cell by Giannopoulos, Chiu, and Praticò, reported that antileukotriene therapy — a class of drugs commonly used in asthma and allergic conditions — reduced tau phosphorylation, preserved synaptic integrity, and improved cognitive performance in P301S transgenic mice, a well-established model of tauopathy relevant to Alzheimer's disease and frontotemporal dementia.

The retraction notice, published in May 2026, states that an investigation identified image manipulation or duplication within Figures 2C, 3C, 4A, and 4C. Additionally, problematic overlap was found with a previously published article from the same author group. These findings rendered the data and conclusions unreliable. The corresponding author, Domenico Praticò, agreed to the retraction. Co-authors Giannopoulos and Chiu were notified but did not respond.

The implications extend beyond this single paper. Antileukotriene agents such as montelukast have attracted growing interest as potential neurological therapeutics, and this retracted study may have contributed to that enthusiasm. Researchers and clinicians should audit any work that cited or built upon these findings.

This case also underscores the broader reproducibility crisis in preclinical Alzheimer's research. High-profile retractions in this space — including those involving amyloid data — highlight the need for independent replication, rigorous image verification, and transparent data sharing before preclinical results are elevated to clinical relevance.